Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from two Phase 3 clinical trials assessing the safety and efficacy of once-daily dosing of the investigational drug linaclotide in patients with chronic constipation (CC). Analyses of the data indicate that in both multicenter, randomized, double-blind, placebo-controlled trials, statistical significance was achieved for the primary endpoint of 12-week complete spontaneous bowel movement (CSBM) overall responder at the two doses studied in each trial (133 mcg/day: p-values≤0.0012 and 266 mcg/day: p-values
Recent Posts
- Randomized Controlled Trial Finds Masimo PVI Improves Fluid Management During Surgery
- Some Children Are Born With "Temporary Deafness"
- High Blood Pressure Linked To Slower Gait And Impaired Mobility
- RNs Charge Jackson Health System, Service Union Broke State Law In Harassment Of Hospital Nurses
- Fighting The Treacherous Hepatitis B
- Dangerous To Draw Wrong Conclusions From New Congenital Heart Disease Research, Says Charity
- New Therapy Shows Promise For Fighting Treatment-Resistant Cancer Cells
- Forest Laboratories Receives Decision From FDA For Supplemental New Drug Application For Bystolic(R)
- Researchers Determine Predicting Factors Of Positive Lung Cancer Diagnoses In Chest Radiographs
- CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed In Terms Of Safety And Efficacy
- People With Mental Health Disabilities Fare Worse In Discrimination Lawsuits